In this week's episode we’ll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.

Subscribe today via iTunes   Google Play    Spotify to receive notification of each new episode as it's published.

 

The articles highlighted in this episode are listed below:

• CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

  Authors: Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent, Hubert Hackl, Ivan M. Borrello, Bruce R. Blazar, Katerina Hatzi, Ivana Gojo, Leo Luznik

• ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

  Authors: Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

• Preclinical efficiency of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias

  Authors: Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst, Vineet Pande, Ann Marien, Dries Goffin, Daniela V. Wenge, Hong Yue, Jevon A. Cutler, Cyrus Jin, Florian Perner, Shanna M. Hogeling, Paul L. Shaffer, Frank Jacobs, Petra Vinken, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Balpreet Bhogal, Karin Verstraeten, Sara El Ashkar, Jennifer A. Perry, Prathiba Jayaguru, Laura Barreyro, Anna Kuchnio, Nicolas Darville, Daniel Krosky, Gregor Urbanietz, Bie Verbist, James P. Edwards, Glenn S. Cowley, Robert Kirkpatrick, Ruth Steele, Lucille Ferrante, Christina Guttke, Nikki Daskalakis, E. Christine Pietsch, David M. Wilson, Ricardo Attar, Yusri Elsayed, Eric S. Fischer, Jan Jacob Schuringa, Scott A. Armstrong, Kathryn Packman, Ulrike Philippar